Spatial transcriptomics in cancer research and potential clinical impact: a narrative review
- PMID: 38850363
- PMCID: PMC11162383
- DOI: 10.1007/s00432-024-05816-0
Spatial transcriptomics in cancer research and potential clinical impact: a narrative review
Abstract
Spatial transcriptomics (ST) provides novel insights into the tumor microenvironment (TME). ST allows the quantification and illustration of gene expression profiles in the spatial context of tissues, including both the cancer cells and the microenvironment in which they are found. In cancer research, ST has already provided novel insights into cancer metastasis, prognosis, and immunotherapy responsiveness. The clinical precision oncology application of next-generation sequencing (NGS) and RNA profiling of tumors relies on bulk methods that lack spatial context. The ability to preserve spatial information is now possible, as it allows us to capture tumor heterogeneity and multifocality. In this narrative review, we summarize precision oncology, discuss tumor sequencing in the clinic, and review the available ST research methods, including seqFISH, MERFISH (Vizgen), CosMx SMI (NanoString), Xenium (10x), Visium (10x), Stereo-seq (STOmics), and GeoMx DSP (NanoString). We then review the current ST literature with a focus on solid tumors organized by tumor type. Finally, we conclude by addressing an important question: how will spatial transcriptomics ultimately help patients with cancer?
Keywords: Genetics; Precision oncology; Solid tumors; Spatial transcriptomics; Tumor microenvironment.
© 2024. Crown.
Conflict of interest statement
Michael A Cilento: declares no potential competing interests. Christopher J Sweeney: Consulting or Advisory Role: Sanofi, Janssen, Astellas Pharma, Bayer, Genentech, Pfizer, Lilly, MDS, Point Biopharma; Research Funding: Janssen Biotech (Inst), Astellas Pharma (Inst), Sanofi (Inst), Bayer (Inst), Patents, Royalties, Other Intellectual Property: Parthenolide (Indiana University): dimethylaminoparthenolide (Leuchemix); Exelixis: Abiraterone plus cabozantinib combination; FRAS1 SNP and tristetraprolin as biomarkers of lethal prostate cancer. Stock or Other Ownership: Leuchemix. Lisa M Butler: declares no potential competing interests.
Figures
References
-
- Al-Dalahmah O, Argenziano MG, Kannan A, Mahajan A, Furnari J, Paryani F, Boyett D, Save A, Humala N, Khan F, Li J, Lu H, Sun Y, Tuddenham JF, Goldberg AR, Dovas A, Banu MA, Sudhakar T, Bush E, Canoll P (2023) Re-convolving the compositional landscape of primary and recurrent glioblastoma reveals prognostic and targetable tissue states. Nat Commun 14(1):2586. 10.1038/s41467-023-38186-1 - PMC - PubMed
-
- Andersson A, Larsson L, Stenbeck L, Salmén F, Ehinger A, Wu SZ, Al-Eryani G, Roden D, Swarbrick A, Borg Å, Frisén J, Engblom C, Lundeberg J (2021) Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions. Nat Commun 12(1):6012. 10.1038/s41467-021-26271-2 - PMC - PubMed
-
- André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Van Cutsem E, Yang P, Farooqui MZ, Diaz H (2020) Pembrolizumab in microsatellite-instability-high Advanced Colorectal Cancer. N Engl J Med 383(23):2207–2218. 10.1056/NEJMoa2017699. Jr - PubMed
-
- Arora R, Cao C, Kumar M, Sinha S, Chanda A, McNeil R, Samuel D, Arora RK, Matthews TW, Chandarana S, Hart R, Dort JC, Biernaskie J, Neri P, Hyrcza MD, Bose P (2023) Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response. Nat Commun 14(1):5029. 10.1038/s41467-023-40271-4 - PMC - PubMed
-
- Asp M, Bergenstråhle J, Lundeberg J (2020) Spatially resolved transcriptomes-Next Generation Tools for tissue exploration. BioEssays 42(10):e1900221. 10.1002/bies.201900221 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous